Get the Stockscreener App
32.92
0.00%
0.00
Agios Pharmaceuticals Inc stock is traded at $32.92, with a volume of 765.24K.
It is up +0.00% in the last 24 hours and up +16.49% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
See More
Previous Close:
$32.92
Open:
$32.97
24h Volume:
765.24K
Relative Volume:
0.83
Market Cap:
$1.93B
Revenue:
$54.03M
Net Income/Loss:
$-412.78M
P/E Ratio:
-4.6243
EPS:
-7.1189
Net Cash Flow:
$-377.29M
1W Performance:
-6.48%
1M Performance:
+16.49%
6M Performance:
-18.94%
1Y Performance:
+30.07%
1-Day Range:
$32.47
$33.17
1-Week Range:
$32.47
$35.99
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
32.92 | 1.93B | 54.03M | -412.78M | -377.29M | -7.1189 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Agios gains on plans to seek FDA accelerated nod for Pyrukynd label expansion - MSN
Published on: 2026-04-10 10:39:14 - baoquankhu1.vn
Exit Recap: Is Agios Pharmaceuticals Inc stock good for income investors2026 Macro Impact & Fast Moving Trade Plans - baoquankhu1.vn
What Agios Pharmaceuticals (AGIO)'s FDA-Backed Accelerated Path for Mitapivat in Sickle Cell Disease Means For Shareholders - Sahm
(AGIO) Risk Channels and Responsive Allocation - Stock Traders Daily
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today - AOL.com
Agios Pharmaceuticals Insider Sells $102,047 in Stock - National Today
Agios Pharmaceuticals Insider Sells $102K in Shares - National Today
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $113,848.80 in Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CFO Cecilia Jones Sells 3,141 Shares - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $113,224.02 in Stock - marketbeat.com
AGIO: JP Morgan Raises Price Target to $36, Maintains Neutral Ra - GuruFocus
Agios Pharmaceuticals CLO sells $113,848 in stock By Investing.com - Investing.com Canada
Jones Cecilia, Agios Pharmaceuticals CFO, sells $109k in stock By Investing.com - Investing.com India
Jones Cecilia, Agios Pharmaceuticals CFO, sells $109k in stock - Investing.com
Agios (NASDAQ: AGIO) CLO exercises 8,500 PSUs and sells shares for taxes - Stock Titan
[Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Agios (NASDAQ: AGIO) CFO exercises PSUs, automatic share sale for taxes - Stock Titan
Agios (AGIO) CCO vests 8,500 PSUs, sells 3,262 shares for taxes - Stock Titan
Agios (NASDAQ: AGIO) exec sells shares to cover PSU tax obligations - Stock Titan
Agios (AGIO) CEO settles performance units, sells 19K shares to cover taxes - Stock Titan
JPMorgan Chase & Co. Raises Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $36.00 - MarketBeat
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET - Bitget
J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Announces Target Price $36 - Moomoo
Short Squeeze: Is Agios Pharmaceuticals Inc stock overvalued or fairly priced2026 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn
Agios to Host First Quarter 2026 Financial Results Conference Call - National Today
Agios will webcast first-quarter results before markets open April 29 - Stock Titan
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
A Look At Agios Pharmaceuticals (AGIO) Valuation As It Pursues Accelerated FDA Approval For Mitapivat - Sahm
AGIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AGIO SEC FilingsAgios Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Agios Pharmaceuticals, Inc. (AGIO) stock price, news, quote and history - Yahoo Finance Australia
Agios to seek accelerated approval in US of oral mitapivat for SCD - Sickle Cell Disease News
[144] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
AGIO (NASDAQ: AGIO) pre-sale notice — 3,141 RSU shares vesting - Stock Titan
Insider sale and RSU vesting at AGIO (Nasdaq: AGIO) — 2,959 shares - Stock Titan
RSU vesting triggers proposed Common Stock sale for AGIO (AGIO) - Stock Titan
AGIO (NASDAQ: AGIO) affiliate files to sell 2,940 shares after RSU vesting - Stock Titan
3,280 RSUs vest; James Burns sold 5,218 shares — AGIO (NASDAQ: AGIO) - Stock Titan
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - qz.com
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - MarketBeat
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - The Globe and Mail
AGIO Shares Climb as Mitapivat Advances Toward Fast-Track Approval for SCD - bitget.com
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - Finviz
A Look At Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Momentum - Yahoo Finance
Earnings Recap: Is Agios Pharmaceuticals Inc a good ESG investment2026 Sector Review & Fast Moving Trade Plans - baoquankhu1.vn
Agios to pursue accelerated approval for mitapivat in sickle cell By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $65 - Moomoo
The Surprise FDA Move That Sent Two Biotechs Rallying - Investor's Business Daily
Why is Agios Pharmaceuticals stock surging Tuesday afternoon? - MSN
Agios (AGIO) Files for Accelerated Approval of Mitapivat in Sick - GuruFocus
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
3.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):